June 11, 2020
Call for proposals yields one of world’s largest COVID-19 portfolios
June 11, 2020, CLEVELAND, Ohio USA – The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, in collaboration with Morgan Stanley GIFT (Global Impact Funding Trust) Cures, today announced 12 award winners in the COVID-19 Rapid Response Initiative. These award recipients will receive grant funding and expert drug development support to advance novel therapies, next-generation vaccines and vaccine alternatives to fight COVID-19 and avert future pandemics. The winners were selected from among hundreds of applications submitted by physicians and scientists at 122 universities and health systems across the U.S., Canada and the United Kingdom.
The call for proposals is part of a major initiative to galvanize the institute’s transatlantic network of academic institutions, foundations, and philanthropic partners to rapidly respond to the global pandemic. In further action, Harrington Discovery Institute will seek to organize development of COVID-19 therapies derived from academia broadly, accelerate breakthrough treatments within its portfolio, and raise capital to resource this effort through Morgan Stanley GIFT Cures, its philanthropic partnership with Morgan Stanley.
“The response to the call for proposals has far exceeded our expectations. The quality of science and potential for clinical impact are truly remarkable. Frankly, there are probably 50 projects here that show promise to protect the nation and the world,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation and Professor of Medicine at University Hospitals and Case Western Reserve University.
Four types of projects are represented in the portfolio:
The award recipients, their organizations and forms of therapy are:
Michael Barry, PhD – Mayo Clinic
Novel Vaccine Against COVID-19
Katherine Fitzgerald, PhD – University of Massachusetts
Fumarate Based Therapeutics and Clinical Trial for Lung Injury
Benjamin Gaston, MD – Indiana University
Novel Agent To Accelerate Ventilator Weaning for Patients With COVID-19 Lung Infection
Jeffrey Glenn, MD, PhD – Stanford University
Single Dose Antiviral Therapeutic for COVID-19
Anastasia Khvorova, PhD – University of Massachusetts
Multi-Virus Therapy for COVID-19 and Other Pandemic-Causing Viruses
Yulia Komarova, PhD – University of Illinois
Novel Therapy for Acute Respiratory Distress
Anne Moscona, MD – Columbia University
Intranasal Agent to Block COVID-19 Infection
Michel Nussenzweig, MD, PhD – The Rockefeller University
Human Antibodies to Prevent and Treat COVID-19
James Reynolds, PhD – University Hospitals of Cleveland /Case Western Reserve University
First Multipurpose Drug to Improve Lung and Heart Function in COVID-19 Patients
Joseph Vinetz, MD – Yale University
Antiviral Clinical Effects of Camostat Mesylate in Early COVID-19+ Outpatients
James Wells, PhD – University of California, San Francisco
Novel Multi-Target Antibodies for COVID-19 Infection
James Wilson, MD, PhD – University of Pennsylvania
Novel Intranasal Vaccine Alternative for COVID-19 Prophylaxis
Since its founding in 2012, Harrington Discovery Institute has supported more than 120 drugs-in-the-making from 54 institutions and has expanded its model into Canada and the United Kingdom.
We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. It is mandatory to procure user consent prior to running these cookies on your website.